Hims & Hers Health Inc SEC Filings

Hims & Hers Health (HIMS) insider filing: Chief Legal Officer Soleil Boughton reported a sale of Class A Common Stock on 10/27/2025. The Form 4 lists a sale of 2,637 shares at a price of $50.10 per share, coded “S.” Following the transaction, the reporting person beneficially owns 158,493 shares, held directly.

The filing notes the trades were effected under a Rule 10b5-1 trading plan adopted on August 28, 2024. This disclosure reflects personal share transactions by an officer and does not describe company operating results.

Hims & Hers Health (HIMS) filed a Form 144 notice for the proposed sale of up to 2,637 shares of its Class A common stock. The filing lists an aggregate market value of $132,113.70, an approximate sale date of 10/27/2025, execution through Fidelity Brokerage Services LLC, and the listing on the NYSE.

The shares were acquired on 09/15/2025 via restricted stock vesting as compensation, in the same amount of 2,637 shares. Recent activity by the same seller shows additional open-market transactions in the past three months, including 2,572 shares on 07/28/2025 for $150,976.40 and 2,637 shares on 09/29/2025 for $155,029.23.

Hims & Hers Health (HIMS) reported an insider transaction by its Chief Financial Officer. On 10/17/2025, the CFO exercised stock options for 7,785 shares at $5.01 and 3,807 shares at $11.53, then sold 11,592 Class A shares at a weighted average price of $57.1275. These trades were made under a Rule 10b5-1 trading plan adopted on May 21, 2025.

Following the transactions, the CFO beneficially owned 70,232 Class A shares directly. Derivative holdings following the transactions included 174,380 options (exercise price $5.01; expiration 02/23/2032) and 56,169 options (exercise price $11.53; expiration 03/01/2033).

Hims & Hers Health (HIMS) CEO and 10% owner Andrew Dudum reported multiple insider transactions on 10/16/2025 under a Rule 10b5-1 plan adopted on August 28, 2024. He exercised stock options at an exercise price of $2.43 and sold shares in several tranches at weighted average prices disclosed within ranges, including $62.50–$62.87, $62.215–$63.13, and $63.31–$63.59.

Reported option exercises included 108,334 and 17,001 shares, followed by sales such as 39,531, 39,332, 39,111, 17,001, and smaller lots. After the transactions, reported direct holdings included 109,190 shares, with additional indirect holdings across multiple family trusts, each listed with its own balance.

Hims & Hers Health, Inc. (HIMS) filed a Form 144 notice for a proposed sale of up to 175,661 Class A shares through Fidelity Brokerage Services, with an aggregate market value of $11,029,998.25. The filing lists the NYSE as the exchange and an approximate sale date of 10/16/2025. Shares outstanding were 217,641,958.

The shares to be sold were acquired via an option grant (125,335 shares) exercised for cash on 10/16/2025 and restricted stock vestings on 06/15/2024 (2,792 shares), 09/15/2023 (4,182 shares), and 06/15/2023 (43,352 shares).

Recent sales over the past three months include examples such as 125,335 Class A shares on 07/21/2025 for $6,208,636.66 and 128,127 Class A shares on 09/16/2025 for $6,852,297.12.

Hims & Hers Health (HIMS) reported a Form 4 for Chief Commercial Officer Michael Chi. On 10/10/2025, he exercised 900 stock options at $6.82 and sold 900 Class A shares at $58.25, executed under a Rule 10b5-1 trading plan adopted on March 4, 2025. Following these transactions, he held 291,439 Class A shares directly and 115,362 derivative securities. The options vest over four years, with 1/48th vesting on September 10, 2022 and monthly thereafter.

Hims & Hers Health (HIMS) disclosed an insider transaction by its Chief Legal Officer. On 10/13/2025, the officer sold 2,637 shares of Class A common stock at $54.38 per share (Transaction Code S) and held 161,130 shares directly after the sale. The sales were effected under a Rule 10b5-1 trading plan adopted on August 28, 2024.

Hims & Hers Health, Inc. notice reports a proposed sale of 900 Class A shares through Fidelity Brokerage Services LLC on 10/10/2025 with an aggregate market value of $52,425. The filer indicates the shares derive from an option granted on 08/10/2022 and show cash payment on the stated sale date. The filing lists recent insider sales by Michael Y. Chi totaling $4,240,268.50 across eight transactions between 07/23/2025 and 10/01/2025.

The notice includes the required representation that the seller does not possess undisclosed material adverse information and identifies this as a Rule 144 notice of proposed sale. No earnings, guidance, or other operational metrics are disclosed in this form.

Insider transactions on 10/03/2025: the Chief Financial Officer, Oluyemi Okupe, adopted a Rule 10b5-1 plan and executed option exercises and open-market sales. The reporting shows 11,595 shares sold at an average weighted price of $57.7173 (range $57.41–$58.09), and two option exercises: 7,787 options at an exercise price of $5.01 and 3,808 options at $11.53. Post-transaction holdings include reported direct ownership entries for Class A common stock and optioned shares underlying 182,165 and 59,976 share tallies respectively as disclosed. The Form states vesting schedules for the options and notes sales were made under the 10b5-1 plan.